Vol. 6 No. 2 (2026)
Reimbursement Reviews

Crovalimab (Piasky)

decorative image of the issue cover

Published February 2, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses crovalimab (Piasky), solution, 340 mg/2 mL (170 mg/mL) for SC injection and IV infusion.
  • Indication: Recommended maintenance dosage: 680 mg (body weight ≥ 40 kg to < 100 kg) or 1,020 mg (≥ 100 kg) by SC injection once every 4 weeks, after 1 loading dose of 1,000 mg (≥ 40 kg to < 100 kg) or 1,500 mg (≥ 100 kg) by IV infusion and 4 additional weekly doses of 340 mg by SC injection.